Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on ...
Hosted on MSN11mon
Doctors protest cost of Vertex cystic fibrosis drug as its scientists prepare to receive $3 million ‘Oscars of Science’ awardThe Vertex scientists are among 11 winners sharing five $3 million Breakthrough Prizes awarded in life sciences, fundamental physics, and mathematics. The foundation has awarded more than $300 ...
In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...
The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%. Vertex’s earnings surpassed the Zacks ...
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...
Explore Vertex Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VRTX. Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...
There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and AppLovin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback